NYSE: GSK
Glaxosmithkline Plc Stock

GSK Price
$35.22
Fair Value Price
N/A
Market Cap
$94.73B
52 Week Low
$31.85
52 Week High
$47.89
P/E
18.75x
P/B
8.31x
P/S
2.85x
PEG
0.97x
Dividend Yield
5.79%
Revenue
$33.75B
Earnings
$4.65B
Gross Profit Margin
64.9%
Operating Margin
19.29%
Net Profit Margin
13.8%
Debt to Equity
5.38
Operating Cash Flow
$10B
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
57
Industry average

Reasons for this score

GSK ($35.22) is trading below its intrinsic value of $147.26, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
GSK is good value based on its earnings relative to its share price (18.75x), compared to the US market average 42.6x)
Valuation
GSK is good value based on its earnings relative to its share price (18.75x), compared to the US Drug Manufacturers - General industry average (-10.13x)
Valuation

1 of 13

GSK News

Valuation

GSK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
18.75x
Industry
-10.13x
Market
42.6x
GSK is good value based on its earnings relative to its share price (18.75x), compared to the US market average 42.6x)
Valuation
GSK is good value based on its earnings relative to its share price (18.75x), compared to the US Drug Manufacturers - General industry average (-10.13x)
Valuation

GSK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.31x
Industry
7.86x
Market
62.61x
GSK is good value based on its book value relative to its share price (8.31x), compared to the US market average (62.61x)
Valuation
GSK is poor value based on its book value relative to its share price (8.31x), compared to the US Drug Manufacturers - General industry average (7.86x)
Valuation

GSK price to earnings growth (PEG)

For valuing profitable companies with growth potential
GSK is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.97x)
Valuation

GSK's financial health

Profit margin

Revenue
$33.8B
Net Income
$4.6B
Profit Margin
13.8%
GSK's Earnings (EBIT) of $6.51B can safely cover interest payments on company debt ($30.51B)
Financials
GSK's profit margin has increased (+2%) in the last year from (11.8%) to (13.8%)
Financials

Assets to liabilities

Assets
$79.7B
Liabilities
$61.3B
Debt to equity
2.67
GSK's short-term liabilities ($24.05B) exceed its short-term assets ($19.49B)
Financials
GSK's long-term liabilities ($37.29B) exceed its short-term assets ($19.49B)
Financials
GSK's debt relative to shareholder equity (5.38) has decreased or remained constant compared to 5 years ago (8.38)
Financials
GSK's debt to equity ratio (5.38) is considered high
Financials

Cash flow

Operating
$9.5B
Investing
-$5.4B
Financing
-$1.8B
GSK's operating cash flow ($9.53B) is sufficient to service the company's debt ($30.51B)
Financials

Glaxosmithkline Stock FAQ

(NYSE: GSK) Glaxosmithkline trades on the NYSE under the ticker symbol GSK. Glaxosmithkline stock quotes can also be displayed as NYSE: GSK.
(NYSE: GSK) Glaxosmithkline stock price per share is $35.22 today (as of Oct 26, 2020).
(NYSE: GSK) Glaxosmithkline's 52-week high was $47.89, and its 52-week low was $31.85. It is currently -26.46% from its 52-week high and 10.58% from its 52-week low.
(NYSE: GSK) Glaxosmithkline's market cap is $94.73B, as of Oct 27, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Glaxosmithkline's market cap is calculated by multiplying GSK's current stock price of $35.22 by GSK's total outstanding shares of 5379067624.
(NYSE: GSK) Glaxosmithkline currently has 5379067624 outstanding shares. With Glaxosmithkline stock trading at $35.22 per share, the total value of Glaxosmithkline stock (market capitalization) is $94.73B.

Glaxosmithkline stock was originally listed at a price of $47.88 in Dec 31, 1997. If you had invested in Glaxosmithkline stock at $47.88, your return over the last 22 years would have been -26.43%, for an annualized return of -1.39%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics